Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;34(8):e13143.
doi: 10.1111/jne.13143. Epub 2022 Aug 18.

Glucose and lipid metabolism abnormalities in Cushing's syndrome

Affiliations
Review

Glucose and lipid metabolism abnormalities in Cushing's syndrome

Rezvan Salehidoost et al. J Neuroendocrinol. 2022 Aug.

Abstract

Prolonged excess of glucocorticoids (GCs) has adverse systemic effects leading to significant morbidities and an increase in mortality. Metabolic alterations associated with the high level of the GCs are key risk factors for the poor outcome. These include GCs causing excess gluconeogenesis via upregulation of key enzymes in the liver, a reduction of insulin sensitivity in skeletal muscle, liver and adipose tissue by inhibiting the insulin receptor signalling pathway, and inhibition of insulin secretion in beta cells leading to dysregulated glucose metabolism. In addition, chronic GC exposure leads to an increase in visceral adipose tissue, as well as an increase in lipolysis resulting in higher circulating free fatty acid levels and in ectopic fat deposition. Remission of hypercortisolism improves these metabolic changes, but very often does not result in full resolution of the abnormalities. Therefore, long-term monitoring of metabolic variables is needed even after the resolution of the excess GC levels.

Keywords: Cushing's syndrome; adipose tissue; glucocorticoids; glucose metabolism disorders; liver; muscles.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
    1. Kunøe A, Sevelsted A, Chawes BL, et al. Associations between inhaled corticosteroid use in the first 6 years of life and obesity-related traits. Am J Respir Crit Care Med. 2021;204:642-650.
    1. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev. 2014;7:1-110.
    1. de Leonibus C, Attanasi M, Roze Z, et al. Influence of inhaled corticosteroids on pubertal growth and final height in asthmatic children. Pediatr Allergy Immunol. 2016;27:499-506.
    1. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632-642.

LinkOut - more resources